SlideShare a Scribd company logo
Metabolic passage –
              its costs and benefits




GITA                         Roman Paškulin, M.D., Ph.D.
Vancouver, 2012                  OMI Institute, Slovenia
Iboga - Tabernanthe iboga
Traditional use:


Tonic and stimulant
Reconvalescence after diseases
Ritual substance – initiation into adulthood
Religious use
Addiction interrupter:


Reduction of symptoms and signs of abstinence syndrome
Acceleration of detoxification
Tolerance reversion
Elimination of cravings
Influence on diverse receptors, transporters and enzymes

Effects last longer than the presence of ibogaine in the body

Long half-life of metabolite

Neurotrophin (GDNF) synthesis and release

Functional and structural remodeling - gene expression and
  proteome changes
Structural proteins-
   cytoskeleton
Functional proteins-
enzymes, receptors, transporters
2-D electrophoresis
Quantification of changes
Peptide mapping by mass spectrometry
Ibogaine 20 mg/kg i.p. 24 and 72h



Enzyme              Accession     Fold      Fold      Theoretical   Score   Matched
                    number        over      over      Mr(Da)/ pI            peptides
                                  control   control
                                  24 h      72 h

Glyceraldehyde-3-   Q9QWU4        1.13      3.21      36090/8.14    62      9
phosphate
dehydrogenase


Malate              42476181      1.42      3.64      36117/8.79    54      9
dehydrogenase

Aldolase A          6978487       1.23      2.45      39783/8.05    60      9


Pyruvate kinase     206205        1.38      2.94      58314/7.19    70      10
Metabolism of glucose – ATP production
Ibogaine 1 mg/l in media 5h


Spot Enzyme          Swiss-Prot     Fold        Theor.       Matched    Mascot
                     Accession      Ibogaine/   Mr(Da)/pI    peptides   score
                     number         Control
Glyceraldehyde-3-    P00359         6.3         35747/6.46   16         381
phosphate
dehydrogenase 3
Phosphoglycerate     P00540         4.6         44738/7.11   19         492
kinase

Enolase 2            P00925         3.8         46914/5.67   22         933
(2-phosphopyruvate
dehydratase 2)

Alcohol              P00330         3.2         36823/6.26   29         694
dehydeogenase 1

Superoxide           P00445         2.2         15855/5.62   7          125
dismutase (Cu-Zn)
ATP pool under ibogaine



                             0
regarding the control (%)
Difference in ATP pool




                            -10


                            -20


                            -30


                                                                     1 g/L
                            -40
                                                                     4 g/L
                                                                     20 g/L
                            -50
                                  0   1       2         3        4    5
                                          Time of exposure (h)
Carbon dioxide production



                                               1,6
                                                                                   1 mg/l
                                               1,4
Production of CO2 relative to control (fold)




                                                                                   4 mg/l
                                               1,2                                 20 mg/l
                                               1,0

                                               0,8

                                               0,6

                                               0,4

                                               0,2

                                               0,0

                                               -0,2

                                               -0,4

                                                      0   1     2         3    4       5
                                                                    Time (h)
Protein synthesis




                  Treated            Control         Ratio               Ratio
                  Σ Normalized       Σ Normalized    (Treated/Control)   (Corrected)
                  Volumes (%)        Volumes (%)

High Abundance
Proteins          36.398             50.103          0.726               1
(Normalized
Volume ≥ 0.5 %)

Low Abundance
Proteins          63.602             49.897          1.275               1.756
(Normalized
Volume < 0.5 %)
ATP pool after ibogaine


                            100

                            80
regarding the control (%)
Difference in ATP pool




                            60

                            40

                            20

                             0

                            -20

                            -40
                                  -10   0   10      20     30      40       50   60   70
                                                 Time after washing (min)
Stabile metabolic shift in the epigenetic landscape
Ibogaine pharmacodynamics
Influence on the total oxidative load


                 1,8

                 1,6

                 1,4

                 1,2
Relative value




                 1,0

                 0,8

                 0,6

                 0,4

                 0,2

                 0,0
                       K   0,2 mg/l    1 mg/l    4 mg/l   20 mg/l   100 mg/l
                                  Concentration of Ibogaine
Influence on the total oxidative load



Calculated      Ibogaine        Oxidative load    Ascorbic acid   Oxidative load
ibogaine        concentration   ratio             concentration   reduction by
concentration   in cytosol      treated/control   [µM]            ascorbic acid
[mg/l]          [mg/l]          [%]

1               0,83 ± 0,03     76,26 ± 1,69      1               non-significant

4               3,89 ± 0,06     76,67 ± 1,56      2               non-significant

20              18,14 ± 0,34    43,45 ± 1,30      4               non-significant
Why do you need narcotics Mr. Lee?

I need junk to get out of the bed in the morning, to shave
and eat breakfast. I need it to stay alive.

                              William S. Burroughs, Junkie
It is not that a warrior learns shamanism as time goes by;
rather, what he learns as time goes by is to save energy.
This energy will enable him to handle some of the energy
fields which are ordinarily inaccessible to him.
Shamanism is a state of awareness; the ability to use energy
fields that are not employed in perceiving the everyday-life
world that we know.

                                          Carlos Castaneda
Increased energy availability




•   accelerates metabolic turnover,
    facilitates metabolic adaptations -
    detoxification and reversal of tolerance
•   enhances mental agility, elevates mood
    and life will
•   facilitates introspection and insight into
    one’s own pathology, helps to locate
    and solve the problem
•   eliminates cravings and protects against
    recidive
Study showed that ibogaine’s influence on
metabolism is neither species nor tissue specific

Effect is not mediated by binding of ibogaine to
receptors previously described in the literature

Ibogaine shows remedial effect in different
pathological conditions, while in health it helps to
resist stress in the adaptogene manner
Pharmacodynamics of Entheogen Drugs –
                Influence on Gene Expression




OMI, Institute for Anthropological Medicine (www.omi.si)

University of Ljubljana, Slovenia
Universite Montpellier 1, France
University of Belgrade, Serbia

More Related Content

What's hot

Session 2 part 2
Session 2 part 2Session 2 part 2
Session 2 part 2plmiami
 
Cell Culture Techniques and Best Practices
Cell Culture Techniques and Best PracticesCell Culture Techniques and Best Practices
Cell Culture Techniques and Best Practices
Thermo Fisher Scientific
 
Evaluation of antioxidant properties of pomegranate peel extract in compariso...
Evaluation of antioxidant properties of pomegranate peel extract in compariso...Evaluation of antioxidant properties of pomegranate peel extract in compariso...
Evaluation of antioxidant properties of pomegranate peel extract in compariso...
Pritam Kolge
 
Unijules product list
Unijules product listUnijules product list
Unijules product listssirajd
 

What's hot (6)

Session 2 part 2
Session 2 part 2Session 2 part 2
Session 2 part 2
 
Cell Culture Techniques and Best Practices
Cell Culture Techniques and Best PracticesCell Culture Techniques and Best Practices
Cell Culture Techniques and Best Practices
 
Ad922 1915
Ad922 1915Ad922 1915
Ad922 1915
 
Session 28 ic2011 jenkins
Session 28 ic2011 jenkinsSession 28 ic2011 jenkins
Session 28 ic2011 jenkins
 
Evaluation of antioxidant properties of pomegranate peel extract in compariso...
Evaluation of antioxidant properties of pomegranate peel extract in compariso...Evaluation of antioxidant properties of pomegranate peel extract in compariso...
Evaluation of antioxidant properties of pomegranate peel extract in compariso...
 
Unijules product list
Unijules product listUnijules product list
Unijules product list
 

Similar to October 3 - Roman Paskulin

Levulinic Acid Reactor and Process Development
Levulinic Acid Reactor and Process DevelopmentLevulinic Acid Reactor and Process Development
Levulinic Acid Reactor and Process Development
Maria Toth
 
3. 정병화식약청 사업단_심포지움_2011
3. 정병화식약청 사업단_심포지움_20113. 정병화식약청 사업단_심포지움_2011
3. 정병화식약청 사업단_심포지움_2011drugmetabol
 
Elephant Sunshine
Elephant SunshineElephant Sunshine
Elephant Sunshine
siteons
 
Thesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 pThesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 p
GavinMDublin
 
2009 Convegno Malattie Rare Benigni [23 01]
2009 Convegno Malattie Rare Benigni [23 01]2009 Convegno Malattie Rare Benigni [23 01]
2009 Convegno Malattie Rare Benigni [23 01]
cmid
 
Vitamin E TPGS Story
Vitamin E TPGS StoryVitamin E TPGS Story
Vitamin E TPGS Story
StephenWu
 
UW-Madison's 2011 iGEM presentation
UW-Madison's 2011 iGEM presentationUW-Madison's 2011 iGEM presentation
UW-Madison's 2011 iGEM presentation
Eric Walters
 
Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...
Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...
Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...
jeni_anggrek10
 
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteinslehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
krupal parmar
 
Inorganic enzyme - a new approach of origin of life
Inorganic enzyme - a new approach of origin of lifeInorganic enzyme - a new approach of origin of life
Inorganic enzyme - a new approach of origin of lifehuangxiaolan
 
Ef coop meetingpres_01192012
Ef coop meetingpres_01192012Ef coop meetingpres_01192012
Ef coop meetingpres_01192012hrlubbers
 
Ibu validation(tanmoy) new
Ibu  validation(tanmoy)  newIbu  validation(tanmoy)  new
Ibu validation(tanmoy) new
Tanmoy Das
 
Defense soheila abachi- june2021
Defense soheila abachi- june2021Defense soheila abachi- june2021
Defense soheila abachi- june2021
Université Laval
 
Luminescent bacteria test aditya parmar
Luminescent bacteria test   aditya parmarLuminescent bacteria test   aditya parmar
Luminescent bacteria test aditya parmarAditya Parmar
 
Luminescent bacteria test, aditya parmar
Luminescent bacteria test,  aditya parmarLuminescent bacteria test,  aditya parmar
Luminescent bacteria test, aditya parmaraparmar85
 
Acs1001 Normal Laboratory Value
Acs1001 Normal Laboratory ValueAcs1001 Normal Laboratory Value
Acs1001 Normal Laboratory Valuemedbookonline
 
2022 FDA Approved Small Molecule Drugs_Part 1.pdf
2022 FDA Approved Small Molecule Drugs_Part 1.pdf2022 FDA Approved Small Molecule Drugs_Part 1.pdf
2022 FDA Approved Small Molecule Drugs_Part 1.pdf
RubiksChemistry
 

Similar to October 3 - Roman Paskulin (20)

Levulinic Acid Reactor and Process Development
Levulinic Acid Reactor and Process DevelopmentLevulinic Acid Reactor and Process Development
Levulinic Acid Reactor and Process Development
 
3. 정병화식약청 사업단_심포지움_2011
3. 정병화식약청 사업단_심포지움_20113. 정병화식약청 사업단_심포지움_2011
3. 정병화식약청 사업단_심포지움_2011
 
Elephant Sunshine
Elephant SunshineElephant Sunshine
Elephant Sunshine
 
Thesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 pThesis presentation gm dt480.4 p
Thesis presentation gm dt480.4 p
 
Avances .ppsx
Avances .ppsxAvances .ppsx
Avances .ppsx
 
2009 Convegno Malattie Rare Benigni [23 01]
2009 Convegno Malattie Rare Benigni [23 01]2009 Convegno Malattie Rare Benigni [23 01]
2009 Convegno Malattie Rare Benigni [23 01]
 
Vitamin E TPGS Story
Vitamin E TPGS StoryVitamin E TPGS Story
Vitamin E TPGS Story
 
UW-Madison's 2011 iGEM presentation
UW-Madison's 2011 iGEM presentationUW-Madison's 2011 iGEM presentation
UW-Madison's 2011 iGEM presentation
 
Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...
Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...
Extraction And Characterization Of Protease From The Viscera Of Skipjack Tuna...
 
ACE Poster
ACE PosterACE Poster
ACE Poster
 
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteinslehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
 
Inorganic enzyme - a new approach of origin of life
Inorganic enzyme - a new approach of origin of lifeInorganic enzyme - a new approach of origin of life
Inorganic enzyme - a new approach of origin of life
 
Ef coop meetingpres_01192012
Ef coop meetingpres_01192012Ef coop meetingpres_01192012
Ef coop meetingpres_01192012
 
Dimitrios Zabaras
Dimitrios ZabarasDimitrios Zabaras
Dimitrios Zabaras
 
Ibu validation(tanmoy) new
Ibu  validation(tanmoy)  newIbu  validation(tanmoy)  new
Ibu validation(tanmoy) new
 
Defense soheila abachi- june2021
Defense soheila abachi- june2021Defense soheila abachi- june2021
Defense soheila abachi- june2021
 
Luminescent bacteria test aditya parmar
Luminescent bacteria test   aditya parmarLuminescent bacteria test   aditya parmar
Luminescent bacteria test aditya parmar
 
Luminescent bacteria test, aditya parmar
Luminescent bacteria test,  aditya parmarLuminescent bacteria test,  aditya parmar
Luminescent bacteria test, aditya parmar
 
Acs1001 Normal Laboratory Value
Acs1001 Normal Laboratory ValueAcs1001 Normal Laboratory Value
Acs1001 Normal Laboratory Value
 
2022 FDA Approved Small Molecule Drugs_Part 1.pdf
2022 FDA Approved Small Molecule Drugs_Part 1.pdf2022 FDA Approved Small Molecule Drugs_Part 1.pdf
2022 FDA Approved Small Molecule Drugs_Part 1.pdf
 

More from ibogainealliance

October 4 - Tanea Paterson
October 4 - Tanea PatersonOctober 4 - Tanea Paterson
October 4 - Tanea Patersonibogainealliance
 
October 2 - Francis Martin Lopez
October 2 - Francis Martin LopezOctober 2 - Francis Martin Lopez
October 2 - Francis Martin Lopezibogainealliance
 
October 2 - Miguel Angel Bianucci
October 2 - Miguel Angel BianucciOctober 2 - Miguel Angel Bianucci
October 2 - Miguel Angel Bianucciibogainealliance
 
October 5 - Tom Kingsley Brown
October 5 - Tom Kingsley BrownOctober 5 - Tom Kingsley Brown
October 5 - Tom Kingsley Brownibogainealliance
 
October 5 - Tanea Patterson
October 5 - Tanea PattersonOctober 5 - Tanea Patterson
October 5 - Tanea Pattersonibogainealliance
 

More from ibogainealliance (10)

October 4 - Tanea Paterson
October 4 - Tanea PatersonOctober 4 - Tanea Paterson
October 4 - Tanea Paterson
 
October 3 - Chris Jenks
October 3 - Chris JenksOctober 3 - Chris Jenks
October 3 - Chris Jenks
 
October 2 - Geoff Noller
October 2 - Geoff NollerOctober 2 - Geoff Noller
October 2 - Geoff Noller
 
October 2 - Francis Martin Lopez
October 2 - Francis Martin LopezOctober 2 - Francis Martin Lopez
October 2 - Francis Martin Lopez
 
October 2 - Miguel Angel Bianucci
October 2 - Miguel Angel BianucciOctober 2 - Miguel Angel Bianucci
October 2 - Miguel Angel Bianucci
 
October 5 - Tom Kingsley Brown
October 5 - Tom Kingsley BrownOctober 5 - Tom Kingsley Brown
October 5 - Tom Kingsley Brown
 
October 5 - Tanea Patterson
October 5 - Tanea PattersonOctober 5 - Tanea Patterson
October 5 - Tanea Patterson
 
October 3 - Bob Sisko
October 3 - Bob SiskoOctober 3 - Bob Sisko
October 3 - Bob Sisko
 
October 3 - Adrian Auler
October 3 - Adrian AulerOctober 3 - Adrian Auler
October 3 - Adrian Auler
 
October 4 - Anwar Jeewa
October 4  - Anwar JeewaOctober 4  - Anwar Jeewa
October 4 - Anwar Jeewa
 

October 3 - Roman Paskulin

  • 1. Metabolic passage – its costs and benefits GITA Roman Paškulin, M.D., Ph.D. Vancouver, 2012 OMI Institute, Slovenia
  • 3. Traditional use: Tonic and stimulant Reconvalescence after diseases Ritual substance – initiation into adulthood Religious use
  • 4. Addiction interrupter: Reduction of symptoms and signs of abstinence syndrome Acceleration of detoxification Tolerance reversion Elimination of cravings
  • 5. Influence on diverse receptors, transporters and enzymes Effects last longer than the presence of ibogaine in the body Long half-life of metabolite Neurotrophin (GDNF) synthesis and release Functional and structural remodeling - gene expression and proteome changes
  • 6. Structural proteins- cytoskeleton
  • 9.
  • 11. Peptide mapping by mass spectrometry
  • 12. Ibogaine 20 mg/kg i.p. 24 and 72h Enzyme Accession Fold Fold Theoretical Score Matched number over over Mr(Da)/ pI peptides control control 24 h 72 h Glyceraldehyde-3- Q9QWU4 1.13 3.21 36090/8.14 62 9 phosphate dehydrogenase Malate 42476181 1.42 3.64 36117/8.79 54 9 dehydrogenase Aldolase A 6978487 1.23 2.45 39783/8.05 60 9 Pyruvate kinase 206205 1.38 2.94 58314/7.19 70 10
  • 13. Metabolism of glucose – ATP production
  • 14. Ibogaine 1 mg/l in media 5h Spot Enzyme Swiss-Prot Fold Theor. Matched Mascot Accession Ibogaine/ Mr(Da)/pI peptides score number Control Glyceraldehyde-3- P00359 6.3 35747/6.46 16 381 phosphate dehydrogenase 3 Phosphoglycerate P00540 4.6 44738/7.11 19 492 kinase Enolase 2 P00925 3.8 46914/5.67 22 933 (2-phosphopyruvate dehydratase 2) Alcohol P00330 3.2 36823/6.26 29 694 dehydeogenase 1 Superoxide P00445 2.2 15855/5.62 7 125 dismutase (Cu-Zn)
  • 15. ATP pool under ibogaine 0 regarding the control (%) Difference in ATP pool -10 -20 -30 1 g/L -40 4 g/L 20 g/L -50 0 1 2 3 4 5 Time of exposure (h)
  • 16. Carbon dioxide production 1,6 1 mg/l 1,4 Production of CO2 relative to control (fold) 4 mg/l 1,2 20 mg/l 1,0 0,8 0,6 0,4 0,2 0,0 -0,2 -0,4 0 1 2 3 4 5 Time (h)
  • 17.
  • 18. Protein synthesis Treated Control Ratio Ratio Σ Normalized Σ Normalized (Treated/Control) (Corrected) Volumes (%) Volumes (%) High Abundance Proteins 36.398 50.103 0.726 1 (Normalized Volume ≥ 0.5 %) Low Abundance Proteins 63.602 49.897 1.275 1.756 (Normalized Volume < 0.5 %)
  • 19. ATP pool after ibogaine 100 80 regarding the control (%) Difference in ATP pool 60 40 20 0 -20 -40 -10 0 10 20 30 40 50 60 70 Time after washing (min)
  • 20. Stabile metabolic shift in the epigenetic landscape
  • 22. Influence on the total oxidative load 1,8 1,6 1,4 1,2 Relative value 1,0 0,8 0,6 0,4 0,2 0,0 K 0,2 mg/l 1 mg/l 4 mg/l 20 mg/l 100 mg/l Concentration of Ibogaine
  • 23. Influence on the total oxidative load Calculated Ibogaine Oxidative load Ascorbic acid Oxidative load ibogaine concentration ratio concentration reduction by concentration in cytosol treated/control [µM] ascorbic acid [mg/l] [mg/l] [%] 1 0,83 ± 0,03 76,26 ± 1,69 1 non-significant 4 3,89 ± 0,06 76,67 ± 1,56 2 non-significant 20 18,14 ± 0,34 43,45 ± 1,30 4 non-significant
  • 24. Why do you need narcotics Mr. Lee? I need junk to get out of the bed in the morning, to shave and eat breakfast. I need it to stay alive. William S. Burroughs, Junkie
  • 25. It is not that a warrior learns shamanism as time goes by; rather, what he learns as time goes by is to save energy. This energy will enable him to handle some of the energy fields which are ordinarily inaccessible to him. Shamanism is a state of awareness; the ability to use energy fields that are not employed in perceiving the everyday-life world that we know. Carlos Castaneda
  • 26. Increased energy availability • accelerates metabolic turnover, facilitates metabolic adaptations - detoxification and reversal of tolerance • enhances mental agility, elevates mood and life will • facilitates introspection and insight into one’s own pathology, helps to locate and solve the problem • eliminates cravings and protects against recidive
  • 27. Study showed that ibogaine’s influence on metabolism is neither species nor tissue specific Effect is not mediated by binding of ibogaine to receptors previously described in the literature Ibogaine shows remedial effect in different pathological conditions, while in health it helps to resist stress in the adaptogene manner
  • 28. Pharmacodynamics of Entheogen Drugs – Influence on Gene Expression OMI, Institute for Anthropological Medicine (www.omi.si) University of Ljubljana, Slovenia Universite Montpellier 1, France University of Belgrade, Serbia